Alfacell forms development, production deal with German cancer center

By Elaine Rigoli

Tampa, Fla., July 11 - Alfacell Corp. announced a new collaboration with the West German Cancer Center at the University of Duisburg-Essen for the development, characterization and large-scale production of a novel fusion protein for non-Hodgkin's lymphoma.

The company said the fusion protein consists of Onconase (ranpirnase) and a humanized anti-CD22 monoclonal antibody.

This fusion protein and other new molecular forms of Onconase will specifically target tumor cells by attaching to antigens on the cell surface. These antigens will specifically internalize Onconase, thereby increasing its tumor cell killing ability, officials said.

Alfacell is a biopharmaceutical company based in Bloomfield, N.J.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.